- Trial phase
- Preclinical / Early-stage (no registered clinical trials found)
- Time to market
- Not stated
- Why 2/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for ABV-1504 in the next ~12 months. The drug appears to be in preclinical or very early-stage development with no registered clinical trials found. ABVC has multiple pipeline assets, so ABV-1504 is not a single make-or-break program.
ABV-1504 has no near-term binary catalyst scheduled. The next meaningful event would be a clinical trial initiation or update from ABVC or its Chinese licensee Xinnovation Therapeutics, but no such date is publicly available. Watch for any press releases on Phase 2/3 trial starts or licensing milestone payments.
Price Chart
Executive Summary
ABV-1504 is a natural/botanical drug candidate for Major Depressive Disorder (MDD) being developed by ABVC BioPharma (NASDAQ: ABVC), a clinical-stage micro-cap biopharmaceutical company. The drug has secured US and Japanese patent protection and was licensed to Xinnovation Therapeutics for the Chinese market in August 2023 under a deal with up to $20M in licensing fees and 5-12% royalties. However, no clinical trial records were found for ABV-1504, suggesting it remains in preclinical or very early-stage development. ABVC itself faces severe financial headwinds: zero revenue, a going concern warning, a working capital deficit, and reliance on dilutive financings. With no near-term binary catalyst, ABV-1504 is a high-risk, early-stage asset within a financially strained company.
How It Works
ABV-1504 is a natural/botanical drug candidate being developed to treat Major Depressive Disorder (MDD). It is part of ABVC's CNS (central nervous system) pipeline. The exact mechanism of action has not been publicly detailed, but as a botanical product, it is derived from plant-based sources.
Trial Status
No clinical trial records for ABV-1504 were found in the SecBot or ClinicalTrials.gov databases. The company has indicated it is eyeing Phase III trials for its depression therapies, but no trial initiations or data readouts have been publicly announced.
The Two-Sided Case
Upcoming Catalysts
- Potential clinical trial initiation announcement for ABV-1504
- Licensing milestone payments from Xinnovation Therapeutics
- Additional patent grants in other territories
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ABVC BIOPHARMA, INC. 424B4 ABVC ·Originating report